HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Eclampsia in pregnancy — Clinical Guidelines

Overview

Eclampsia is a severe complication of preeclampsia characterized by the onset of seizures during pregnancy or postpartum, posing significant risks to both maternal and fetal health 1 2.

Diagnosis

Seizures in a patient with preeclampsia 1 2.

Hypertension (≥140/90 mmHg) with proteinuria 1 2.

Laboratory tests: Elevated liver enzymes, thrombocytopenia, and renal impairment may support the diagnosis 4.

Monitoring for signs of HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelet count) 4.

Management

First-line treatment: Intravenous magnesium sulfate for seizure control and prevention 1 2 3.

Dosage: Typically, loading dose of 4-6 g followed by maintenance dose of 1-2 g/hour 3.

Cardiology care: Consideration of predelivery cardiology evaluation, especially in high-risk populations, to mitigate future cardiovascular risks 1.

Hemodynamic support: Management of hemorrhage and hepatic complications with appropriate surgical interventions if necessary 4.

Special Populations

Pregnancy: Focus on timely administration of magnesium sulfate to prevent and control seizures 1 2 3.

Comorbidities: Higher vigilance for cardiovascular outcomes post-delivery, particularly in Black patients who show higher incidence of major adverse cardiovascular events 1.

Key Recommendations

Use intravenous magnesium sulfate as the first-line treatment for eclampsia to control seizures and prevent recurrence (Evidence: Strong 1 3).

Evaluate and manage cardiovascular risk factors pre-delivery, especially in high-risk racial groups, to reduce future MACE risk (Evidence: Moderate 1).

Ensure comprehensive healthcare system support, including trained personnel and adequate resources, for effective management of eclampsia in resource-limited settings (Evidence: Expert opinion 2).

References

1 Bolakale-Rufai IK, Knapp SM, Tucker Edmonds B, Khan S, Brewer LC, Mohammed S et al.. Relationship Between Race, Predelivery Cardiology Care, and Cardiovascular Outcomes in Preeclampsia/Eclampsia Among a Commercially Insured Population. Circulation. Cardiovascular quality and outcomes 2025. link 2 Goldenberg RL, McClure EM. It Takes a System: Magnesium Sulfate for Prevention of Eclampsia in a Resource-Limited Community Setting. Global health, science and practice 2019. link 3 Lotufo FA, Parpinelli MA, Osis MJ, Surita FG, Costa ML, Cecatti JG. Obstetrician's risk perception on the prescription of magnesium sulfate in severe preeclampsia and eclampsia: A qualitative study in Brazil. PloS one 2017. link 4 Aziz S, Merrell RC, Collins JA. Spontaneous hepatic hemorrhage during pregnancy. American journal of surgery 1983. link90311-2)

Eclampsia in pregnancy